NJSOP Society of Optometric Physicians

SPRING CONTINUING EDUCATION SERIES

VIRTUAL EVENT | APRIL 10-11, 2021

5 TPA/1 Oral NJSBO Credits - COPE Approved

Diabetes Head to Toe: What Optometrists Should Know About Systemic Diabetes, Non-Ocular Comorbidities and their Link to Eye Disease

Current Treatment of Diabetes

Marijuana, Cannabis, Cannabinoids Glaucoma and IOP

Marijuana and Driving: Your Retina and Brain

Sensory Systems and Neurodegenerative Processes

Featured Speakers:

Paul Chous, OD -and- Denise Valenti, OD

Don’t miss the virtual exhibit hall & raffles!

Spring CE Seminar | Schedule & Pricing

SATURDAY, April 10, 2021 | 12:30pm - 4:00pm

12:30p – 1:00p	**Exhibit Hall Opens**
1:00p - 2:30p	**Diabetes Head to Toe: What Optometrists Should Know About Systemic Diabetes, Non-Ocular Comorbidities and Their Link to Eye Disease -- Paul Chous, OD** COPE #71156-SD – 1.5 hrs. NJSBO TPA Credit
2:30p – 2:45p	**NJSOP Diamond & Gold Partner Presentations**
2:45p - 3:00p	**Exhibit Hall Break**
3:00p - 3:05p	**Raffle Drawing - Eligibility: Visit a minimum of four virtual exhibit booths today!**
3:05p - 4:30p	**Current Treatment of Diabetes -- Paul Chous, OD** COPE # 71157-SD – 1.5 hrs. NJSBO TPA Credits

SUNDAY, April 11, 2021 | 8:30am - 12:00pm

8:30a – 9:20a	**Marijuana, Cannabis, Cannabinoids Glaucoma, and IOP -- Denise Valenti, OD** COPE # 71158-GL – 1 hr. NJSBO TPA Credit
9:20a - 9:30a	**NJSOP Diamond & Gold Partner Presentations**
9:30a - 9:45a	**Exhibit Hall Break**
9:45a - 9:50a	**Raffle Drawing - Eligibility: Visit a minimum of two virtual exhibit booths today!**
9:50a - 10:40a	**Marijuana and Driving: Your Retina and Brain -- Denise Valenti, OD** COPE # 71164-PH – 1 hr. NJSBO Oral Credit
10:40a - 10:50a	**NJSOP Diamond & Gold Partner Presentations**
10:50a - 11:05a	**Exhibit Hall Break**
11:05a - 11:10a	**Raffle Drawing - Eligibility: Visit a minimum of four virtual exhibit booths today!**
11:10a - 12:00p	**Sensory Systems and Neurodegenerative Processes -- Denise Valenti, OD** COPE # 71177-NO - 1 hr. NJSBO TPA Credit
12:00p	**Grand Raffle Drawing - Eligibility: Attend both days and visit 8 or more exhibit booths.**

PRICING

2 DAY PRICING	**Member OD $105** **Non-member OD $157.50** **Member Para $45** **Non-Member Para $60**	**1 DAY PRICING** **(Sat. or Sun.)**	**Member OD $70** **Non-member OD $105** **Member Para $30** **Non-Member Para $45**

REGISTER ONLINE HERE

Spring CE Seminar | Course Descriptions

Diabetes Head to Toe: What Optometrists Should Know About Systemic Diabetes, Non-Ocular Comorbidities and Their Link to Eye Disease

This course will cover the biology, diagnosis & consequences of systemic diabetes. Common systemic complications will be considered, especially as they relate to diabetic retinopathy and with an eye to diabetes comorbidities with which eye doctors may have less familiarity.

Current Treatment of Diabetes

This course will consider treatment algorithms for type 1 and type 2 diabetes, with an emphasis on newer therapies, cardio-, reno-, and retino-protection, and game-changing technologies with which every health care provider should be familiar.

Marijuana, Cannabis, Cannabinoids Glaucoma, and IOP

Thirty-six states and the District of Columbia currently have legal medicinal use of marijuana and among these the majority allow for the treatment of glaucoma with medicinal marijuana. However, there is no indication that any state is requiring monitoring of these patients using the accepted standards of medical management with appropriate diagnosis and follow up, to accompany the treatment of glaucoma with medical marijuana. Further there is an increasing body of research that the cannabinoid, Cannabidiol-CBD causes spiking of the eyes pressure. This lecture will review the research related to cannabinoids and marijuana and their use in the treatment of glaucoma. Further the lecture will review how CBD is being used in FDA approved products as well as widely distributed OTC products and the potential for vision harm. The impact of legal recreational and medical marijuana on patients perception of efficacy to treat glaucoma will be discussed.

Marijuana and Driving: Your Retina and Brain

Marijuana impacts cognition and sensory functions. The impairment is enough to create a serious hazard to driving. The rate of drivers testing positive for marijuana only in a fatal accident, has doubled in Washington and Colorado since the legalization of marijuana. Marijuana causes dysfunction in retinal processing. Marijuana inhibits up to 75 of the visual functions in the lateral geniculate nucleus, the primary brain relay nucleus. Little is known about what levels of marijuana and its primary ingredients Cannabidiol CBD and Tetrahydrocannabinol THC, impair functions enough to impact driving. Further there is no functional test available to law enforcement to support dysfunction even when the blood levels of measured THC is considered to be high enough to impair function. There is research using functional Magnetic resonance imaging that the visual system has dysfunction with acute and chronic use of marijuana. This lecture will review the available research related the visual pathway and its relationship to driving and cannabis use.

Sensory Systems and Neurodegenerative Processes

There are normal changes in the sensory systems; vision, hearing and olfaction, with advancing age. However, these same systems have changes with neurodegenerative disease that are not considered normal aging. Diseases such as Alzheimer's and Parkinson's diseases can have sensory system changes that impact function and quality of life. Recognizing sensory dysfunction that is not within the continuum of normal aging can result in earlier treatments and interventions. More recently there has been recognition that the residual effects of COVID may also cause sensory dysfunctions that persist. This lecture will discuss the current body of knowledge regarding sensory impairment, aging and disease with the emphasis on olfaction.

Spring CE Seminar | Speakers

A. Paul Chous, MA, OD, FAAO

Dr. Chous completed his undergraduate education at Brown and UC Irvine, and then received his Masters and Doctorate of Optometry degrees from UC Berkeley. Paul has a private practice specializing in diabetes eye care and education in Tacoma, WA. He is the author of Diabetic Eye Disease: Lessons From a Diabetic Eye Doctor, which was included in the "Top 12 Diabetes Books" by Diabetes Update magazine in 2004. He is editorial advisor to Review of Optometry and Optometry Times, AOA representative to the National Diabetes Education Program, Primary Investigator for the Diabetes Visual Function Supplement Study (DiVFuSS), and an adjunct Professor of Optometry at Western University of Health Sciences in Pomona, CA.

Denise A. Valenti, OD

Dr. Valenti is a residency-trained, low-vision/blind-rehabilitation optometrist with additional education and expertise in the field of age-related neurodegenerative diseases with the emphasis on Parkinson's disease and Alzheimer's disease. Dr. Valenti has had additional training as an MGH/MIT/HMS Functional MRI Fellow at the Martinos Center for Biomedical Imaging in Boston, Massachusetts and participated in the year long seminar series offered through the Boston University Sleep Disorders Center Fellowship program. Her research has included the study of imaging of retinal neural tissue using Optical Coherence Tomography and functional assessment of neural processing in the visual system using Frequency Doubling Technology. Dr. Valenti taught Clinical Low Vision at NECO from 1985-87 and Ferris State University – College of Optometry from 1987-91. She most recently taught Low Vision and Geriatrics at the MCPHS University School of Optometry and Gerontology at Quincy College and continues to provide medical content to numerous professional newsletters throughout the United States. Dr. Valenti provided direct clinical care for more than 25 years and currently is active in research and consultation related to vision, aging, neuroprocessing and cognitive functions. She is currently the owner of IMMAD-Impairment Measurement Marijuana and Driving. The company provides education, services, and technology for the responsible use of cannabis. The current emphasis is on the technology IMMAD. IMMAD is a two minute objective test for law enforcement use to determine fitness to drive with marijuana consumption.

Don't forget to visit our virtual exhibit hall during scheduled breaks to be entered to win raffle prizes!

REGISTER ONLINE HERE

NJSOP OD
Society of Optometric Physicians

Questions? Contact the NJSOP at (609) 323-4012